Shire up after earnings

Shire plc (LSE:SHP; NASDAQ:SHPGY) was up 37p to 919p on Wednesday after reporting 2Q09 earnings. Shire reported revenues of $629.7 million, beating the Street's estimate of $622.6 million. Revenues fell 19% from $775.6 million in 2Q08, primarily due to a 77% decline in sales of ADHD drug Adderall XR, which became available as a generic in the U.S. in April. Excluding Adderall XR, product sales grew 20% over the prior year's quarter. Sales of ADHD drug Vyvanse lisdexamfetamine sales came in at $114 million, up 75% from 2Q08. ...